← All Biolinerx LTD filings

Biolinerx LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
BLRX
Biolinerx LTD
20-F/A: BioLineRx Amends 20-F for Auditor Consent Correction
BioLineRx Ltd. filed an amended annual report on Form 20-F/A to correct the date in its auditor's consent and refile executive certifications.
NASDAQ
BLRX
Biolinerx LTD
20-F: BioLineRx Refocuses on Oncology, Rare Diseases Amidst Going Concern Warning
BioLineRx Ltd. shifts strategic focus to oncology and rare diseases after out-licensing its approved drug APHEXDA, despite ongoing significant losses and a 'going concern' warning from management.
NASDAQ
BLRX
Biolinerx LTD
20-F: BioLineRx Issues Placement Agent Warrant for American Depositary Shares
BioLineRx grants a placement agent warrant to purchase American Depositary Shares, outlining terms, exercise conditions, and adjustment clauses.
NASDAQ
BLRX
Biolinerx LTD
20-F/A: BioLineRx Amends 20-F Filing to Correct Typographical Error
BioLineRx files an amendment to its 20-F report to correct a typographical error in the independent auditor's report and re-file an exhibit.
NASDAQ
BLRX
Biolinerx LTD
20-F: BioLineRx 20-F Filing: Details Financials, APHEXDA Launch, and Future Strategy
BioLineRx's 20-F filing highlights APHEXDA's FDA approval and U.S. launch, alongside financial results and strategic plans.